Verapamil
As of the edition of 20 October 2026, Verapamil is a small molecule: marketed, first approved in 1964 (ES); acts on CACNA1C, CACNA1D and CACNA1F and 1 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1987
- Kind
- Small molecule
- Brand name
- Isoptin
- First approved
- 1 June 1964 (ES)
- Approvals on record
- 31 in 4 regions
- Holder of the most recent approval
- Exela Pharma Sciences; 9 holders in all
- Registered trials
- 72, 8 stopped early
- Disease areas
- Heart and blood vessels; Nervous system; Nutrition and metabolism; Hormones; Immune system; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
8 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product8 company-target rows are on route B because of Verapamil.
See the 8 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 10 | 5 | 2 | 2 |
| Phase 1 | 34 | 29 | 0 | 3 |
| Phase 2 | 11 | 4 | 4 | 2 |
| Phase 3 | 4 | 4 | 0 | 0 |
| Phase 4 | 13 | 7 | 2 | 1 |
| All trials | 72 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Elan Pharmaceuticals | Later holder | 1990 to now |
| Pfizer | Acquired holder, Later holder and Lead sponsor of trials | 1992 to now |
| Mt Adams Technologies | Acquired holder | 2015 to now |
| Exela Pharma Sciences | Acquired holder | 2015 to now |
| Azurity Pharmaceuticals | Acquired holder | 2024 to now |
| Eisai | Applicant |